Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 10/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23964326 | 0.90 | MAP1LC3B (0.44) | MAP1LC3BALDH1A1ALOX15TSHRMAPK1 | |
| SCHEMBL23964331 | 0.90 | ALDH1A1 (0.40) | MAP1LC3BALDH1A1ALOX15TSHRMAPK1 | |
| SCHEMBL23964481 | 0.80 | ALDH1A1 (0.40) | MAP1LC3BALDH1A1ALOX15TSHRMAPK1 | |
| SCHEMBL31282322 | 0.76 | MAP1LC3B (0.59) | MAP1LC3BALDH1A1ALOX15TSHRMAPK1 | |
| SCHEMBL26172950 | 0.75 | KCNH2 (0.39) | ALDH1A1MAPK1KCNA3KCNH2 | |
| SCHEMBL26172965 | 0.74 | THRB (0.50) | ALDH1A1MAPK1KCNA3KCNH2 | |
| SCHEMBL23930168 | 0.74 | THRB (0.50) | ALDH1A1MAPK1KCNA3KCNH2 | |
| SCHEMBL26172951 | 0.73 | MAP1LC3B (0.58) | MAP1LC3BALDH1A1ALOX15TSHRMAPK1 | |
| SCHEMBL26172963 | 0.70 | KCNH2 (0.53) | MAPK1KCNA3KCNH2 | |
| SCHEMBL23964537 | 0.69 | ALDH1A1 (0.44) | MAP1LC3BALDH1A1ALOX15TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
| WO-2021213518-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | 复旦大学 (CN) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | MAP1LC3B, MAP1LC3A, SQSTM1 | MAP1LC3B 1/4885ALDH1A1 897/4885ALOX15 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.